ArticleBMC gastroenterology2025
Feasibility, efficacy, and safety of ventral caudal artery access for transarterial chemoembolization in a rat hepatocellular carcinoma model.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeInvestigate the feasibility, efficacy, and safety of ventral caudal artery (VCA) approach for transarterial chemoembolization (TACE) in an orthotopic hepatocellular carcinoma (HCC) rat model.
methodsSixteen orthotopically established tumor-bearing Sprague-Dawley rats were divided into two groups of eight each: drug-eluting bead transarterial chemoembolization (DEB-TACE) group and normal saline (NS) group. VCA was approached for transarterial procedures. Rats in DEB-TACE group and NS group received transarterial administration of doxorubicin-loaded microspheres and normal saline, respectively. In NS group, repeated transarterial procedures were attempted 3 days after initial procedures. The feasibility was evaluated based on success rate of VCA approach, proper hepatic artery catheterization, and transcatheter treatment. The efficacy was assessed according to tumor necrosis. Animal mortality and tail viability were observed for safety evaluation. In supplementary experiments, eight additional tumor-bearing rats were used to evaluate the repeatability of proper hepatic artery catheterization via VCA access at 14 days after initial transarterial procedures the same as the NS group. The safety during the 14 days was also evaluated.
resultsVCA was successfully approached in 16 rats at initial procedures. Catheterization of proper hepatic artery achieved success in 7 of 8 DEB-TACE group animals and 6 of 8 NS group animals at initial procedures. All 13 rats received subsequent DEB-TACE or NS injection. One animal in DEB-TACE group died within 24 h and no death was noted in NS group (14.29% vs. 0%, P = 1.000). Tail viability was normal within 3 days. Repeated transarterial procedures were successfully performed in 6 of 8 NS group animals. Tumor necrosis of DEB-TACE group was significantly higher than that of NS group (54.11 ± 22.31% vs. 11.15 ± 3.50%, P = 0.005). In supplementary experiments, repeated catheterization of proper hepatic artery via repeated VCA access was achieved in 7 of 8 rats that had undergone successful initial procedures. There was no death noted and the tail viability maintained normal during the 14 days after initial procedures.
conclusionVCA access is feasible, effective, safe for TACE in rat HCC model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.